Xilio Therapeutics Inc. Common Stock (XLO)
Stock · NASDAQ · Health Care
$8.55as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
XLO Signal Track Record
How signals performed across all stocks →What XLO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 22 | -0.6% | 45% | August 17, 2026 |
| Bollinger Band Breakout | 21 | -3.7% | 33% | June 22, 2026 |
| Bollinger Band Breakdown | 20 | +0.0% | 50% | July 20, 2026 |
| 200-Day Moving Average Touch | 14 | -2.0% | 36% | July 1, 2026 |
| Any 20-session window (baseline) | -1.6% | 43% |
Computed by MarketWall from daily closing prices since August 9, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 76
- Website
- xiliotx.com/
Fundamentals
- 1-day range
- $8.94$9.57
- Market cap
- $60.95M
- P/E (trailing)
- —
- P/E (forward)
- -15.41
- EPS (trailing)
- $-1.54
- Dividend yield
- —
- Beta
- -0.11
- Avg. volume
- 24.0K
Forecasts
1 analyst ratings
Xilio Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- XLOXilio Therapeutics Inc. Common Stock$8.55▼ 5.21%Market cap $60.95MP/E —$6.47$12.74
- HYFTMindWalk Holdings Corp. Common Stock$1.31▼ 6.43%Market cap $59.79MP/E —$0.99$2.99
- PMVPPMV Pharmaceuticals Inc. Common Stock$1.21▼ 6.20%Market cap $62.93MP/E —$1.02$1.91
- DWTXDogwood Therapeutics Inc. Common Stock$1.22▼ 2.40%Market cap $58.85MP/E —$1.24$7.04
- BOLDBoundless Bio Inc. Common Stock$2.34▼ 0.43%Market cap $63.80MP/E —$0.9612$3.16
- ANVSAnnovis Bio Inc. Common Stock$0.99▼ 5.71%Market cap $64.44MP/E —$1.01$5.5
- PLRXPliant Therapeutics Inc. Common Stock$0.9▼ 7.41%Market cap $65.02MP/E —$0.8838$1.95
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| XLO Xilio Therapeutics Inc. Common Stock | $60.95M | — | $8.55 | ▼ 5.21% | $6.47$12.74 |
| HYFT MindWalk Holdings Corp. Common Stock | $59.79M | — | $1.31 | ▼ 6.43% | $0.99$2.99 |
| PMVP PMV Pharmaceuticals Inc. Common Stock | $62.93M | — | $1.21 | ▼ 6.20% | $1.02$1.91 |
| DWTX Dogwood Therapeutics Inc. Common Stock | $58.85M | — | $1.22 | ▼ 2.40% | $1.24$7.04 |
| BOLD Boundless Bio Inc. Common Stock | $63.80M | — | $2.34 | ▼ 0.43% | $0.9612$3.16 |
| ANVS Annovis Bio Inc. Common Stock | $64.44M | — | $0.99 | ▼ 5.71% | $1.01$5.5 |
| PLRX Pliant Therapeutics Inc. Common Stock | $65.02M | — | $0.9 | ▼ 7.41% | $0.8838$1.95 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Curran Daniel J. · June 11, 2026 · Grant5.0K
- Bello Akintunde Olatokumbo · June 11, 2026 · Grant5.0K
- Xu Yuan · June 11, 2026 · Grant5.0K
- ROSS ROBERT W. · June 11, 2026 · Grant5.0K
- Aoife Brennan · June 11, 2026 · Grant5.0K
- Sara Bonstein · June 11, 2026 · Grant5.0K
- James Samuel Shannon · June 11, 2026 · Grant5.0K
- Blanchard Cheryl R · April 15, 2026 · Grant10.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 1.94M
- Total value held
- $16.17M
- Institutional holders
- 20
- Unknown664.0K
- Unknown422.5K
- Unknown152.5K
- Unknown123.7K
- Unknown112.1K
- Unknown106.0K
- Unknown64.2K
- Unknown57.5K
- Unknown49.6K
- Unknown47.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Xilio Therapeutics appoints Yariv J. Houvras as Chief Medical Officer
Xilio Therapeutics announced that Dr. Yariv J. Houvras, M.D., Ph.D., will serve as its new Chief Medical Officer. The appointment adds experienced clinical leadership to the company as it advances its therapeutic pipeline. This change comes while the stock is trading near the top of its 52‑week range, suggesting market attention to the leadership update.
Xilio Therapeutics appoints Yariv J. Houvras as Chief Medical Officer. Xilio Therapeutics announced that Dr. Yariv J. Houvras, M.D., Ph.D., will serve as its new Chief Medical Officer. The appointment adds experienced clinical leadership to the company as it advances its therapeutic pipeline. This change comes while the stock is trading near the top of its 52‑week range, suggesting market attention to the leadership update.